Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
David A. Reardon, Merrill J. Egorin, Annick Desjardins, James J. Vredenburgh, Jan H. Beumer, Theodore F. Lagattuta, Sridharan Gururangan, James E. Herndon II, August J. Salvado, Henry S. FriedmanVolume:
115
Year:
2009
Language:
english
Pages:
11
DOI:
10.1002/cncr.24213
File:
PDF, 297 KB
english, 2009